ACM
CASI

ADAR1 Capital Management’s CASI Pharmaceuticals CASI Stock Holding History

ADAR1 Capital Management’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-44,120
Closed -$52.1K – 228
2025
Q2 		$52.1K Sell
44,120
-3,300
-7% -$6.05K 0.01% 190
2025
Q1 		$102K Buy
47,420
+1,100
+2% +$2.69K 0.02% 165
2024
Q4 		$131K Sell
46,320
-18,515
-29% -$87.8K 0.03% 172
2024
Q3 		$399K Buy
64,835
+56,595
+687% +$366K 0.07% 127
2024
Q2 		$45.3K Buy
+8,240
New +$25.6K 0.01% 191

Other funds holding CASI

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $92.6M AUM 41.64% 1-Year Est. Return

ADAR1 Capital Management's CASI Position: Q3 2025 in Review

ADAR1 Capital Management sold out of CASI Pharmaceuticals (CASI) in Q3 2025, closing a stake of 44,120 shares — an estimated $52.1K sold.

ADAR1 Capital Management first reported a position in CASI in Q2 2024 and held it in 5 quarters. The position peaked at $399K in Q3 2024. 22 funds tracked by Wall St. Rank hold CASI as of Q3 2025.

  • ADAR1 Capital Management reported no remaining CASI Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • ADAR1 Capital Management sold 44,120 CASI Pharmaceuticals shares in Q3 2025, an estimated $52.1K.
  • ADAR1 Capital Management first reported a position in CASI Pharmaceuticals in Q2 2024 and held it in 5 quarters.
  • ADAR1 Capital Management's CASI Pharmaceuticals position peaked at $399K in Q3 2024.
  • 22 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q3 2025.

Based on ADAR1 Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.